Applicability of guideline-informing lipid-lowering clinical trials to contemporary real-world patients with atherosclerotic cardiovascular disease.

ABSTRACT:

Aims

Lipid-lowering randomized clinical trials (RCTs) inform guideline recommendations for secondary prevention of atherosclerotic cardiovascular disease (ASCVD). However, these trials were often conducted decades ago using strict eligibility criteria, which may limit their applicability to today's diverse ASCVD population. This study compared clinical characteristics and long-term outcomes between trial-eligible and ineligible real-world ASCVD patients.

Methods and results

Eligibility criteria from eight pivotal lipid-lowering RCTs were applied to patients with coronary artery disease (CAD), cerebrovascular disease (CeVD), and peripheral artery disease (PAD) in the Utrecht Cardiovascular Cohort-Second Manifestations of ARTerial disease (UCC-SMART) study (2000-2023). The pro

SUBMITTER: Schuitema PCE 

PROVIDER: S-EPMC12714395 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature